Small Cell Lung Carcinoma Clinical Trial
Official title:
Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as First Line Therapy in Chemotherapy Naive Patients With Extensive Disease (ED) Stage Small Cell Lung Cancer (SCLC)
The purpose of this study is to determine whether the study drug is effective and safe in the first line treatment of patients with small cell lung cancer
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05882058 -
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
|
Phase 2 | |
| Terminated |
NCT03963414 -
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
|
Phase 1 | |
| Active, not recruiting |
NCT04358237 -
Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06419179 -
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
|
Phase 2 | |
| Completed |
NCT02874664 -
A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT02397733 -
Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)
|
N/A | |
| Recruiting |
NCT01977235 -
Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00759824 -
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
|
Phase 2 | |
| Active, not recruiting |
NCT03568097 -
Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT02876081 -
Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex
|
Phase 2 | |
| Recruiting |
NCT06247605 -
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04996771 -
Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT03662074 -
Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03232593 -
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
|
||
| Completed |
NCT01941316 -
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT01574300 -
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
|
||
| Recruiting |
NCT06131840 -
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05683977 -
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
|
||
| Recruiting |
NCT04620837 -
Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT05329623 -
A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.
|
Phase 1 |